It mediates neuroprotection by inhibiting Sp1 binding to it target sites in the promoters of oncogenes such as Myc, without affecting its binding to the promoters of tumor suppressors such as p21waf1/cip1 [2]. Here, CDKN1A is linked to neoplasm.